Ibalizumab-uiyk Medication Information

Get detailed information on Ibalizumab-uiyk, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it.

The updated prescription information on Ibalizumab-uiyk provides an overview of possible side effects, precautions, warnings, and storage tips.

You'll also find brand names used in india and internationally, along with pricing details. For further clarification, consult your healthcare provider.

Generic Name : Ibalizumab-uiyk

Pronunciation : eye-ba-LIZ-ue-mab-uiyk

Therapeutic Classification : Monoclonal antibodies

Trade Names/Brand Names of Ibalizumab-uiyk

India :

Trogarzo

Overview of Ibalizumab-uiyk

• Ibalizumab-uiyk injection is a non-immunosuppressive monoclonal antibody approved by FDA in March 2018 to treat adults with multidrug-resistant HIV-1 infection.

Why is Ibalizumab-uiyk Prescribed? (Indications)

Ibalizumab-uiyk intravenous injection is prescribed along with other antiretroviral medications to treat human immunodeficiency virus-1 (HIV-1) infection in adults. It is used for HIV patients with-
• Previous history of antiretroviral therapies
• Multidrug-resistant HIV-1 infection
• Failure or loss of response with other antiretroviral medicines

Ibalizumab-uiyk is a post attachment inhibitor that binds to CD4 glycoprotein, the primary receptor for human immunodeficiency virus and blocks the viral entry process into the immune cells.

When should Ibalizumab-uiyk not be taken? (Contraindications)

Ibalizumab-uiyk should not be used in patients who are-

• Allergic to ibalizumab-uiyk
• Pregnant and breastfeeding
• Below 18 years of age

What is the dosage of Ibalizumab-uiyk?

• The recommended dose of ibalizumab-uiyk is a single loading dose of 2000 mg initially followed by a maintenance dose of 800 mg administered for every two weeks.

• Dose modification is not necessary while treating with other antiretroviral medicines or while undergoing any other treatment.

How should Ibalizumab-uiyk be taken?

• Ibalizumab-uiyk is available as an injection which should be administered by a trained healthcare provider directly into the vein as a slow infusion for about 15 to 30 minutes.

• Ibalizumab-uiyk should only be diluted with 250 ml of 0.9% sodium chloride injection and should be administered within 4 hours if stored at room temperature (below 25°C) or within 24 hours if stored in a refrigerator (2°C to 8°C).

• The refrigerated solution should be allowed to come to room temperature for at least 30 minutes before administration.
• After the completion of each infusion of ibalizumab-uiyk, it is recommended to flush the medication out with 30 ml of 0.9% sodium chloride.
• Any unused portion or partially used vials of ibalizumab-uiyk should be discarded.

What are the warnings and precautions for Ibalizumab-uiyk?

• Patients should be monitored for the risk of immune reconstitution inflammatory syndrome which requires further evaluation and supportive treatment.

• Patients should regularly be monitored for laboratory abnormalities to detect variations of blood sugar level and various markers for blood disorders.

• Levels of bilirubin, creatinine, and uric acid levels should also be evaluated while the patient is on ibalizumab-uiyk treatment.

What are the side effects of Ibalizumab-uiyk?

• Nausea
• Diarrhea
• Dizziness
• Rashes (erythematous, maculopapular or generalized)
• Changes in the immune system

What are the other precautions for Ibalizumab-uiyk?

• The infusion schedule should be followed strictly and should not be changed or stopped without the physician’s advice.
• If a maintenance dose of 800 mg ibalizumab-uiyk is missed for more than three days, a loading dose of 2000 mg should be given as soon as possible followed by a maintenance dose of 800 mg for every two weeks.
• Ibalizumab-uiyk vials should be inspected for the presence of any particulate matter or discoloration. Discard the vials immediately if any of those are found.